555 related articles for article (PubMed ID: 21740097)
1. Durable event-free survival following autologous stem cell transplant for relapsed or refractory follicular lymphoma: positive impact of recent rituximab exposure and low-risk Follicular Lymphoma International Prognostic Index score.
Peters AC; Duan Q; Russell JA; Duggan P; Owen C; Stewart DA
Leuk Lymphoma; 2011 Nov; 52(11):2124-9. PubMed ID: 21740097
[TBL] [Abstract][Full Text] [Related]
2. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
[TBL] [Abstract][Full Text] [Related]
3. Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure.
Jiménez-Ubieto A; Grande C; Caballero D; Yáñez L; Novelli S; Hernández-Garcia MT; Manzanares M; Arranz R; Ferreiro JJ; Bobillo S; Mercadal S; Galeo A; López Jiménez J; Moraleda JM; Vallejo C; Albo C; Pérez E; Marrero C; Magnano L; Palomera L; Jarque I; Martínez-Sánchez P; Martín A; Coria E; López-Guillermo A; Salar A; Lahuerta JJ
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1631-1640. PubMed ID: 28533060
[TBL] [Abstract][Full Text] [Related]
4. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma.
Gisselbrecht C; Schmitz N; Mounier N; Singh Gill D; Linch DC; Trneny M; Bosly A; Milpied NJ; Radford J; Ketterer N; Shpilberg O; Dührsen U; Hagberg H; Ma DD; Viardot A; Lowenthal R; Brière J; Salles G; Moskowitz CH; Glass B
J Clin Oncol; 2012 Dec; 30(36):4462-9. PubMed ID: 23091101
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era.
Sesques P; Bourcier J; Golfier C; Lebras L; Nicolas-Virelizier E; Hacini M; Perrin MC; Voillat L; Bachy E; Traverse-Glehen A; Moreau A; Martin L; Ramla S; Casasnovas O; Le Gouill S; Salles G; Ghesquières H
Hematol Oncol; 2020 Apr; 38(2):137-145. PubMed ID: 31953963
[TBL] [Abstract][Full Text] [Related]
6. Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study.
Brugger W; Hirsch J; Grünebach F; Repp R; Brossart P; Vogel W; Kopp HG; Manz MG; Bitzer M; Schlimok G; Kaufmann M; Ganser A; Fehnle K; Gramatzki M; Kanz L
Ann Oncol; 2004 Nov; 15(11):1691-8. PubMed ID: 15520073
[TBL] [Abstract][Full Text] [Related]
7. Follicular lymphoma at relapse after rituximab containing regimens: comparison of time to event intervals prior to and after 90 Y-ibritumomab-tiuxetan.
Cicone F; Russo E; Carpaneto A; Prior JO; Delaloye AB; Scopinaro F; Ketterer N
Hematol Oncol; 2011 Sep; 29(3):131-8. PubMed ID: 20862654
[TBL] [Abstract][Full Text] [Related]
8. Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation.
Pettengell R; Schmitz N; Gisselbrecht C; Smith G; Patton WN; Metzner B; Caballero D; Tilly H; Walewski JA; Bence-Bruckler I; To B; Geisler CH; Schots R; Kimby E; Taverna CJ; Kozák T; Dreger P; Uddin R; Ruiz de Elvira C; Goldstone AH
J Clin Oncol; 2013 May; 31(13):1624-30. PubMed ID: 23547078
[TBL] [Abstract][Full Text] [Related]
9. Long-term clinical and molecular remissions in patients with follicular lymphoma following high-dose therapy and autologous stem cell transplantation.
Metzner B; Pott C; Müller TH; Gebauer W; Casper J; Kraemer D; Rosien B; Schumann-Binarsch S; Thole R; Köhne CH
Ann Oncol; 2013 Jun; 24(6):1609-15. PubMed ID: 23393125
[TBL] [Abstract][Full Text] [Related]
10. Autologous stem cell transplantation in follicular lymphoma: a systematic review and meta-analysis.
Al Khabori M; de Almeida JR; Guyatt GH; Kuruvilla J; Crump M
J Natl Cancer Inst; 2012 Jan; 104(1):18-28. PubMed ID: 22190633
[TBL] [Abstract][Full Text] [Related]
11. Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study.
Redondo AM; Pomares H; Vidal MJ; Pascual MJ; Quereda B; Sancho JM; Polo M; López J; Conde E; Jarque I; Alonso N; Ramírez MJ; Fernández P; Sayas MJ; Requena MJ; Salar A; González JD; González-Barca E; Arranz R; Caballero D; Martín A
Br J Haematol; 2014 Mar; 164(5):668-74. PubMed ID: 24274082
[TBL] [Abstract][Full Text] [Related]
12. Autologous stem cell transplantation for follicular lymphoma: no benefit for early transplant?
Seyfarth B; Kuse R; Sonnen R; Glass B; Schmitz N; Dreger P
Ann Hematol; 2001 Jul; 80(7):398-405. PubMed ID: 11529465
[TBL] [Abstract][Full Text] [Related]
13. Chemoresistance can be overcome with high-dose chemotherapy and autologous stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.
Gerrie AS; Power MM; Shepherd JD; Savage KJ; Sehn LH; Connors JM
Ann Oncol; 2014 Nov; 25(11):2218-2223. PubMed ID: 25149708
[TBL] [Abstract][Full Text] [Related]
14. Iodine-131 rituximab radioimmunotherapy with BEAM conditioning and autologous stem cell transplant salvage therapy for relapsed/refractory aggressive non-Hodgkin lymphoma.
Kruger PC; Cooney JP; Turner JH
Cancer Biother Radiopharm; 2012 Nov; 27(9):552-60. PubMed ID: 23062193
[TBL] [Abstract][Full Text] [Related]
15. Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result in durable remissions, irrespective of prior rituximab exposure.
Kothari J; Peggs KS; Bird A; Thomson KJ; Morris E; Virchis AE; Lambert J; Goldstone AH; Linch DC; Ardeshna KM
Br J Haematol; 2014 May; 165(3):334-40. PubMed ID: 24438080
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era.
Nagle SJ; Woo K; Schuster SJ; Nasta SD; Stadtmauer E; Mick R; Svoboda J
Am J Hematol; 2013 Oct; 88(10):890-4. PubMed ID: 23813874
[TBL] [Abstract][Full Text] [Related]
17. Effect of prior rituximab on high-dose therapy and autologous stem cell transplantation in follicular lymphoma.
Kang TY; Rybicki LA; Bolwell BJ; Thakkar SG; Brown S; Dean R; Sekeres MA; Advani A; Sobecks R; Kalaycio M; Pohlman B; Sweetenham JW
Bone Marrow Transplant; 2007 Nov; 40(10):973-8. PubMed ID: 17873917
[TBL] [Abstract][Full Text] [Related]
18. Prolonged clinical remissions in patients with relapsed or refractory follicular lymphoma treated with autologous stem cell transplantation incorporating rituximab.
Berinstein NL; Bhella S; Pennell NM; Cheung MC; Imrie KR; Spaner DE; Milliken V; Zhang L; Hewitt K; Boudreau A; Reis MD; Chesney A; Good D; Ghorab Z; Hicks LK; Piliotis E; Buckstein R
Ann Hematol; 2015 May; 94(5):813-23. PubMed ID: 25567231
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas.
Poiré X; Kline J; Grinblatt D; Zimmerman T; Conner K; Muhs C; Gajewski T; Van Besien K; Smith SM
Leuk Lymphoma; 2010 Jul; 51(7):1241-50. PubMed ID: 20496994
[TBL] [Abstract][Full Text] [Related]
20. High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival.
Kim MK; Kim S; Lee SS; Sym SJ; Lee DH; Jang S; Park CJ; Chi HS; Huh J; Suh C
Ann Hematol; 2007 Jun; 86(6):435-42. PubMed ID: 17256144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]